The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET).
Timothy J. Hobday
No relevant relationships to disclose
Rui Qin
No relevant relationships to disclose
Diane Lauren Reidy
Consultant or Advisory Role - Novartis; Pfizer
Research Funding - ImClone Systems; Merck Sharp & Dohme
Malcolm J Moore
No relevant relationships to disclose
Jonathan R. Strosberg
No relevant relationships to disclose
Andreas Kaubisch
No relevant relationships to disclose
Manisha H. Shah
Research Funding - ImClone Systems; NCI; Novartis
Hedy Lee Kindler
Consultant or Advisory Role - Genentech
Research Funding - Pfizer
Heinz-Josef Lenz
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
Helen X. Chen
No relevant relationships to disclose
Charles Erlichman
No relevant relationships to disclose